Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Sinovac COVID-19 vaccine granted conditional market approval in China

    Xinhua | Updated: 2021-02-07 09:35
    Share
    Share - WeChat
    A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, displays two doses of COVID-19 inactivated vaccine in prefilled syringes in Beijing, capital of China, Dec 23, 2020. [Photo/Xinhua]

    BEIJING -- China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday.

    The Sinovac vaccine, produced by the Beijing-based Sinovac Life Sciences Co Ltd, affiliated with Sinovac Biotech, was approved for emergency use in China last June. The vaccine started being used for emergency inoculation among some special groups in the country from July last year.

    From this January, countries including Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos successively approved the emergency use of the Sinovac vaccine locally.

    These countries recognize the clinical research results of the vaccine, believing it has obvious effects on reducing the medical treatment, hospitalization, critical cases and deaths caused by COVID-19, and is of great importance to pandemic prevention and control, Sinovac Biotech said in a press release on its website.

    Sinovac Life Sciences Co Ltd on Feb 3 filed an application for conditional market approval of CoronaVac, which was granted on the basis of the vaccine's overseas phase-3 clinical trials for two months, it said.

    The NMPA requested the company to continue to carry out relevant clinical trials, fulfill the conditional requirements, and submit the follow-up research results in time.

    "We expect to provide more safe and effective vaccines as soon as possible and help control COVID-19 ultimately by increasing inoculation rates, enabling social and economic development to return to the normal track," said Yin Weidong, chairman and CEO of Sinovac.

    According to the company, the vaccination procedure includes two shots with an interval of 14 to 28 days, and each dose is 0.5 ml.

    In China, the vaccine has completed its phase-1 and phase-2 clinical trials for adults aged over 18 and the elderly, and the enrollment of volunteers aged 3 to 17 has been completed. The volunteers in China has reached more than 2,200 people and the results showed that the vaccine has good safety and immunogenicity in all age groups.

    Since July 2020, Sinovac has conducted phase-3 clinical trials in four countries including Brazil, Chile, Indonesia and Turkey, involving more than 25,000 volunteers altogether.

    As of December 16, 2020, 12,396 medical workers aged over 18 were enrolled in Brazil and 253 infection cases were collected during the observation period. Clinical studies in Brazil suggested that the vaccine was 100 percent effective in preventing hospitalized, severe, and fatal cases, 83.7 percent effective in preventing cases requiring medical treatment, and has a general efficacy rate of 50.65 percent.

    Clinical trials in Turkey involved both health care workers aged 18-59 who are at high risk and the general population at normal risk. Results in Turkey showed that the vaccine has an efficacy rate of 91.25 percent.

    The vaccine production quality management system has passed GMP inspections in many countries including China, Brazil, Indonesia and Chile. Hundreds of batches of large-scale production have proved that the vaccine production process is controllable and the quality is reliable.

    Sinovac's first production line which went into operation in August 2020 has an annual production capacity of 500 million doses. The company has constructed a second production line, which will start operation in February, increasing its annual production capacity to 1 billion doses.

    Sinovac will also export semi-finished jabs to some countries with filling and packaging capabilities such as Brazil, Indonesia and Turkey.

    The supply of vaccines in the form of both finished and semi-finished products will help fill the gap of the company's filling and packaging capacity, save the international transportation cost, and improve the accessibility and affordability of vaccines, the company said.

    It is China's second self-developed COVID-19 vaccine that has got conditional market approval in the country. The vaccine developed by China National Biotec Group affiliated with Sinopharm was approved in December last year.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    久久青青草原亚洲av无码app| 最近最新高清免费中文字幕| 惠民福利中文字幕人妻无码乱精品 | 亚洲Av无码专区国产乱码不卡| 毛片免费全部播放无码| 亚洲.欧美.中文字幕在线观看| 无码人妻一区二区三区在线| 在线观看免费中文视频| 成人无码区在线观看| 中文字幕乱码人妻无码久久 | 日韩乱码人妻无码系列中文字幕| 精品无码人妻一区二区三区| 精品久久久无码人妻中文字幕| 日本久久久久久中文字幕| 亚洲中文字幕无码一去台湾| 99热门精品一区二区三区无码| 亚洲AV永久无码区成人网站| 亚洲日韩AV一区二区三区中文 | 精品人妻无码区二区三区| 在线观看免费中文视频| 极品粉嫩嫩模大尺度无码视频| 日日摸日日碰夜夜爽无码| 亚洲AV永久无码精品水牛影视| 色窝窝无码一区二区三区色欲 | 暖暖免费中文在线日本| 中文人妻无码一区二区三区| 无码人妻一区二区三区在线水卜樱| 日韩精品无码一区二区中文字幕| 亚洲av永久无码精品古装片| 亚洲精品无码乱码成人| 寂寞少妇做spa按摩无码| 久久人妻无码中文字幕| 成在人线av无码免费高潮喷水| 国产综合无码一区二区辣椒 | 日韩乱码人妻无码系列中文字幕| 成人无码免费一区二区三区| 亚洲中文字幕无码久久2017| 亚洲AV综合色区无码另类小说| 无码精品A∨在线观看中文| 国产精品无码成人午夜电影| 99久久人妻无码精品系列蜜桃|